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Previous estimates have suggested that venous thrombo-
embolism is responsible for around 60 000 deaths in the UK
each year.1 It is thought that individuals admitted to
hospital may be at increased risk of developing deep vein
thrombosis and/or pulmonary embolism as a result of
reduced mobility or intercurrent illness. Other important
risk factors include older age (over 60 years), active
malignancy, dehydration, inherited or acquired thrombophilia,
obesity, previous venous thromboembolism or family
history of venous thromboembolism, oral contraceptive
pill use, hormone replacement therapy, pregnancy and
varicose veins with phlebitis.2,3 These risk factors may be
applicable to individuals admitted to hospital for medical,
surgical or psychiatric care. For these reasons, current
clinical guidelines recommend a risk assessment for all
people who are admitted to hospital and prescription of a
low-dose anticoagulant such as low molecular weight
heparin (LMWH) and/or mechanical prophylaxis for those
thought to be at high risk.2 The decision as to whether to
offer venous thromboembolism prophylaxis should be
balanced against potential risks, particularly the risk of
bleeding with LMWH.
Evidence base for venous thromboembolism
prophylaxis in acute general hospitals
Numerous interventional studies have investigated the role
of mechanical and pharmacological prophylaxis in reducing
the risk of venous thromboembolism among those admitted
to an acute general hospital. Studies have principally
focused on patients undergoing orthopaedic surgery, non-
orthopaedic surgery or no surgery. Interventional studies
have demonstrated a reduction in symptomatic deep vein
thrombosis among patients undergoing orthopaedic surgery
who receive LMWH (relative risk (RR) = 0.50, 95% CI 0.43-
0.594). The use of LMWH in this group is not associated
with a signiﬁcant increase in major bleeding (RR =0.81, 95%
CI 0.38-1.724). Prophylactic LMWH is also associated with
a reduction in non-fatal symptomatic venous thrombo-
embolism in patients who are undergoing non-orthopaedic
surgery (RR =0.31, 95% CI 0.12-0.815) and possibly a
reduction in symptomatic deep vein thrombosis (RR =0.47,
95% CI 0.22-1.006) and pulmonary embolism (odds ratio
(OR) = 0.70, 95% CI 0.56-0.877) in patients who are not
undergoing surgery. However, this is balanced with a
signiﬁcantly increased risk of major bleeding (OR= 1.28,
1.05-1.567). Furthermore, when considering fatal pulmonary
embolism or overall mortality, prophylactic LMWH is not
associated with signiﬁcant beneﬁt in any group.4-7
Evidence base for venous thromboembolism
prophylaxis in mental healthcare settings
In contrast to studies in acute general hospitals, there is
relatively little published evidence investigating venous
thromboembolism incidence and the role of pharm-
acological or mechanical prophylaxis in mental healthcare
settings. A recent observational study that included
systematic venous ultrasonography identiﬁed deep vein
thrombosis in 10 out of 449 participants (2.2%) following
10 days of admission to a psychiatric hospital.8 A total of
16 out of 458 (3.5%) had experienced an episode of venous
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Summary Venous thromboembolism is an important cause of morbidity and
mortality. In recent years, growing awareness has led to the development of strategies
to prevent venous thromboembolism in individuals admitted to hospital who are
deemed to be at high risk. However, there remains a considerable degree of
uncertainty over whether these strategies are of overall beneﬁt and there are few
published studies on people who are admitted to psychiatric hospitals. In this editorial
I review current clinical practice and areas of uncertainty with respect to venous
thromboembolism prophylaxis and its implementation in mental healthcare settings.
Declaration of interest None.
Venous thromboembolism prophylaxis in mental
healthcare: do the beneﬁts outweigh the risks?
Rashmi Patel1
61
thromboembolism by 90 days following admission. Of these,
three had a non-fatal pulmonary embolism. The study also
showed that venous thromboembolism was more likely in
older people (8.6% of those aged over 75 years), which may
relate to greater exposure to risk factors such as immobility.
Another study based on a review of hospital records
revealed 17 conﬁrmed cases of venous thromboembolism
among 1495 people (1.1%) admitted to an in-patient mental
health service for older people.9 This contrasts with an
incidence of 2.4% within 91 days among people undergoing
total hip arthroplasty surgery10 and 1.45 per 1000 person
years in the general population.11
There is growing evidence from observational studies
that suggests a possible association between antipsychotic
medications and venous thromboembolism, particularly for
clozapine and ﬁrst-generation antipsychotics.12 However, it
has been difﬁcult to establish whether this association could
be a direct pharmacological consequence of antipsychotics
(leading to a prothrombotic state) or if it is mediated
through other risk factors that are consequences of
antipsychotics, such as obesity or sedation leading to
reduced mobility.13 Some studies have also pointed towards
physical restraint as a potential risk factor for venous
thromboembolism in mental healthcare settings.14-16
Areas of uncertainty
A recent meta-analysis has led to increasing controversy
over the potential beneﬁts of pharmacological or
mechanical measures to prevent venous thromboembolism
among hospital patients who are not undergoing surgery.7
Although a reduction in non-fatal symptomatic venous
thromboembolism was seen with LMWH prophylaxis, this is
balanced with an increased risk of bleeding and no overall
beneﬁt in terms of reduced mortality. Furthermore, the
relative beneﬁt of prophylaxis only translates to a modest
reduction in absolute risk; for every 1000 in-patients treated
with LMWH, only three cases of pulmonary embolism are
prevented balanced with four additional cases of major
bleeding.7
There is also continued uncertainty about the true
incidence of clinically signiﬁcant venous thrombo-
embolism.17 Although data from epidemiological modelling
suggests that venous thromboembolism is responsible for
around 60 000 deaths each year in the UK,1 data from post-
mortem studies suggest a much lower rate of around 5680
per year.18 Whether pharmacological and mechanical
prophylaxis could prevent all deaths from venous
thromboembolism is also unclear.
Do people who develop venous thromboembolism
always need treatment with anticoagulants?
Some observational studies have employed systematic
ultrasound screening to identify asymptomatic as well as
symptomatic deep vein thrombosis. Although deep vein
thrombosis was identiﬁed in 10 out of 449 participants
following admission to a psychiatric hospital, seven cases
were of distal deep vein thrombosis of which only one case
was symptomatic.8 The extent to which asymptomatic deep
vein thrombosis predisposes an individual to increased risk
of mortality remains uncertain, particularly with respect to
asymptomatic distal deep vein thrombosis.19
The advent of computed tomography pulmonary
angiography (CTPA) has led to a substantial increase in
the radiological diagnosis of pulmonary embolism.20
However, uncertainty is growing over the optimum
treatment particularly with respect to whether all those
with a radiological diagnosis of pulmonary embolism would
beneﬁt from anticoagulation.21 It is thought that small
subsegmental emboli may not necessarily be associated with
adverse clinical outcomes and that the risks of bleeding
from treatment with anticoagulants may outweigh any
beneﬁts within this group.22
Beneﬁts and risks of venous thromboembolism
prophylaxis in mental healthcare settings
There are no published interventional studies that have
investigated the potential beneﬁts of venous thrombo-
embolism prophylaxis in mental healthcare in-patient
settings. Despite this, there is ongoing interest in developing
and utilising risk-screening tools to identify individuals
at increased risk of venous thromboembolism for
prophylaxis.23 Furthermore, there is no published evidence
that has investigated the potential harms of venous
thromboembolism prophylaxis in this setting. Although
risks of bleeding have been well characterised for people
admitted to acute general hospitals, it is not clear whether
the same risks apply elsewhere. In particular, prolonged use
of LMWH can predispose to thrombocytopenia leading to
an increased risk of bleeding.24 The mean length of stay in
an in-patient mental healthcare setting (adult: 52.1 days,
older people: 93.2 days) is substantially greater than that of
an acute medical unit (5.5 days).25 With the exception of
those taking clozapine, full blood count monitoring is not
routinely performed in the mental healthcare in-patient
setting. The extent to which staff in mental healthcare
settings are trained to administer prophylaxis and recognise
potential adverse complications is also unclear.3 For these
reasons, it is possible that the risk of thrombocytopenia
from LMWH may be greater for those who receive it for
venous thromboembolism prophylaxis in the mental
healthcare setting.
Balancing the potential risks of bleeding and the
potential beneﬁts of preventing venous thromboembolism
with pharmacological prophylaxis is problematic. Cost-
utility analysis is a method by which the beneﬁts and risks
of an intervention may be balanced with respect to quality
of life measures. A study investigating the application of
cost-utility analysis to venous thromboembolism found
that there was a wide degree of variation in individual
estimates of cost-utility of both acute venous thrombo-
embolism and bleeding complications from pharmacological
prophylaxis.26 However, in the mental healthcare in-patient
setting, it is sometimes not possible for patients to weigh up
beneﬁts and risks of an intervention because of lack of
mental capacity. Furthermore, there is little evidence to
estimate the potential beneﬁts and risks of venous
thromboembolism prophylaxis among individuals who lack
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capacity as randomised controlled trials have excluded
these individuals.17
Discussion
Venous thromboembolism remains an important cause of
mortality in people who are admitted to hospital. However,
in recent years, there has been ongoing uncertainty over the
efﬁcacy and risks of prophylaxis among in-patients who are
not undergoing surgery6,7 and whether everyone with
established venous thromboembolism would beneﬁt from
anticoagulant treatment.21,22 Although prophylaxis appears
to reduce the incidence of non-fatal venous thrombo-
embolism, there is no robust evidence that supports a
reduction in mortality.4-7 This may be because of the balance
with risk of bleeding for pharmacological prophylaxis.7,24
There is even less evidence to support its use in mental
healthcare in-patient settings where no interventional
studies have been published.
Despite this, substantial resources (over £30 million
per year in England) have been invested into venous
thromboembolism prevention programmes that claim to
‘save lives’.27 Although it is claimed these investments have
resulted in a modest overall saving (a yield of 2.7%28), it is
possible that there is a greater opportunity cost in mental
healthcare settings where there is currently no evidence
for the cost-effectiveness of venous thromboembolism
prophylaxis.
It is clear that there is an ongoing need to improve the
overall physical health of individuals with mental illness,
particularly those with severe mental illness who have been
shown to have a substantially lower life expectancy than the
general population.29 Although venous thromboembolism is
an important cause of mortality, a greater degree of impact
could be achieved by investing resources into improving
detection and treatment of new cases3 as well as
preventative strategies in mental healthcare for cardio-
vascular disease in general.30 In summary, there is little
evidence to support current strategies for venous thrombo-
embolism prophylaxis in mental healthcare settings.
Further study to develop and evaluate the effectiveness of
novel venous thromboembolism prevention and early
detection strategies is therefore warranted.
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